Lipoprotein insulin resistance index: A lipoprotein particle-derived measure of insulin resistance

Metabolic Syndrome and Related Disorders

Volumn 12, Issue 8, 2014, Pages 422-429

  Shalaurova, Irina ^a   Connelly, Margery A ^a   Garvey, W Timothy ^b   Otvos, James D ^a  

^a LIPOSCIENCE INC   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AFRICAN AMERICAN; AGED; ALGORITHM; ARTICLE; ASIAN AMERICAN; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; EUROPEAN AMERICAN; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE DISPOSAL RATE; HISPANIC; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN INSULIN RESISTANCE INDEX; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OBSERVATIONAL STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROSIS; CHEMISTRY; HOMEOSTASIS; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARTICLE SIZE;

EID: 84907293481     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2014.0050     Document Type: Article

References (37)

1. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-252.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
3. Daniel S, Soleymani T, Garvey WT. A complicationsbased clinical staging of obesity to guide treatment modality and intensity. Cur Opin Endocrinol Diabetes Obes 2013;20:377-388.
4. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A rando mized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161.
5. Garvey WT,Ryan DH,Henry R,et al., Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extendedrelease, Diabetes Care, 2014, 37, 912-921.
6. American Diabetes Association, N ational Institute of Diabetes, Digestive and Kidney Disorders. The prevention or delay of type 2 diabetes. Diabetes Care 2002;25:742-749.
7. Genuth S, Kahn R. A step backward-or is it forward? Diabetes Care 2008;31:1093-1096.
8. Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15-E26.
9. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
10. Pei D, Jones CN, Bhargava R, et al. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 1994;37:843-845.
11. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970;49:2151-216 0.
12. Greenfield MS, Doberne L, Kraemer F, et al. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981;30:387-392.
13. Bergman RN, Ider YZ, Bowden CR, et al. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236: E667-E677.
14. Laakso M, Sarlund H, Mykkane n L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990;10:223-231.
15. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-809.
16. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462.
17. Goff DC, Jr., D? Agostin o RB, Jr., Haffner SM, et al. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54:264-270.
18. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-146.
19. Festa A, Williams K, Hanley AJ, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005;111:3465-3472.
20. Tamez-Perez HE, Proskauer-Pena SL, Hernrndez-Coria MI, et al. AACE Comprehensive Diabetes Management Algorithm 2013 Endocrine Practice. Endocr Pract 2013; 19:736-737.
21. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and design. Am J Epidemiol 2002;156:871-881.
22. Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985;34:222-234.
23. Kennedy A, Gettys TW, Watson P, et al. T he metabolic significance of leptin in humans: Gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 1997;82:1293-1300.
24. Jeyarajah E J, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-870.
25. Clincial and Laboratory Standards Institute. CLSI document EP5-A2: Evaluation of Precision Performance of Quantitative Measurements Methods; Approved Guideline-Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute, 2004.
26. Goldberg R,Temprosa M,Otvos J,et al.,Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program, J Clin Endocrinol Metab, 2013, 98, 3989-3998.
27. Frazier-Wood AC, Garvey WT, Dall T, et al. Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction. Metab Syndr Reatl Disord 2012;10:244-251.
28. Pisprasert V, Ingram KH, Lopez-Davila MF, et al. Limitations in the use of indices using glucose and insulin levels to predict insulin sensiti vity: Impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 2013;36:845-853.
29. Lara-Castro C, Garvey WT. Diet, insulin resistance, and obesity: Zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab 2004;89:4197-4205.
30. Davidson MH, Rooney M, Pollock E, et al. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol 2013;7:423-432.
31. Alvarsson M, Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest 1996;56:563-570.
32. Kelly JJ, Lawson JA, Campbell LV, et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 2000;14:567-572.
33. Poynten AM, Gan SK, Kriketos AD, et al. Ni cotinic acidinduced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 2003;52:699-704.
34. Goldberg RB, Jacobson TA. Eff ects of niacin on glucose control in patients with dyslipidemia. Mayo Clinic Proc 2008;83:470-478.
35. Group HTC. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niac in/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291.
36. Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: Rationale for a complications-centric approach. Endocr Pract 2013;19:864-874.
37. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists? comprehensive diabetes management algorithm 2013 consensus statement- executive summary. Endocr Pract 2013;19:536-557.